Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tiotropium/Salmeterol FDC vs Components in COPD
NCT00673478Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tiotropium and salmeterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve (AUC0-∞) of tiotropium in plasma at 16 weeks, Maximum measured concentration of tiotropium in plasma at 16 weeks and 3 more. Started May 2008; status: completed.
02
Drugs
tiotropiumsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00673478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673478.